Table 3 Univariate and multivariate analysis of overal survival

Age, years (> 60 vs ≤ 60)

1.030 (0.731–1.452)

Gender (Male vs Female)

1.182 (0.749–1.867)

ALT, IU/ml (> 40 vs ≤ 40)

0.768 (0.539–1.095)

AST, IU/ml (> 40 vs ≤ 40)

1.252 (0.893–1.755)

ALP, IU/L (> 130 vs ≤ 130)

1.144 (0.778–1.681)

ALB, g/L (< 35 vs ≥ 35)

1.072 (0.690–1.667)

Total bilirubin, µmol/L (> 17 vs ≤ 17)

1.249 (0.889–1.755)

PT, s (≥ 13 vs < 13)

1.763 (1.132–2.745)

AFP, ng/ml (≥ 20 vs < 20)

1.919 (1.343–2.742)

2.227 (1.513–3.278)

PLT, 10⁹/L (≥ 100 vs < 100)

1.251 (0.864–1.810)

Satellite nodules (yes vs no)

1.741 (1.154–2.627)

Capsular(yes vs no)

1.583 (1.080–2.321)

Moderate/poor tumor differentiation (yes vs no)

1.820 (1.295–2.557)

1.625 (1.150–2.297)

Vascular invasion (yes vs no)

2.345 (1.630–3.373)

1.144 (0.731–1.789)

Tumor size, cm (> 5 vs ≤ 5)

3.037 (2.104–4.384)

2.237 (1.130–4.429)

Multiple tumor (yes vs no)

2.917 (1.965–4.330)

2.021 (1.265–3.228)

Cirrhosis (yes vs no)

1.631 (1.110–2.398)

Hypertension (yes vs no)

1.190 (0.825–1.718)

Diabetes mellitus (yes vs no)

1.170 (0.767–1.784)

History of smoking (yes vs no)

1.203 (0.856–1.691)

Alcohol abuse (yes vs no)

1.215 (0.861–1.714)

HBeAg positive (yes vs no)

1.071 (0.684–1.677)

Child–Pugh score (B vs A)

2.224 (0.707–6.993)

BCLC stage (B-C vs 0-A)

3.153 (2.133–4.661)

1.053 (0.486–2.283)

Antiviral therapy (yes vs no)

0.587 (0.418–0.825)

0.500 (0.343–0.728)